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Abstract
Pyrethroids are widely-used chemical insecticides, to which humans are commonly exposed,
and known to alter functional expression of drug metabolizing enzymes. Limited data have
additionally suggested that drug transporters, that constitute key-actors of the drug det-
oxification system, may also be targeted by pyrethroids. The present study was therefore
designed to analyze the potential regulatory effects of these pesticides towards activities of
main ATP-binding cassette (ABC) and solute carrier (SLC) drug transporters, using trans-
porter-overexpressing cells. The pyrethroids allethrin and tetramethrin were found to inhibit
various ABC and SLC drug transporters, including multidrug resistance-associated protein
(MRP) 2, breast cancer resistance protein (BCRP), organic anion transporter polypeptide
(OATP) 1B1, organic anion transporter (OAT) 3, multidrug and toxin extrusion transporter
(MATE) 1, organic cation transporter (OCT) 1 and OCT2, with IC50 values however ranging
from 2.6 μM (OCT1 inhibition by allethrin) to 77.6 μM (OAT3 inhibition by tetramethrin) and
thus much higher than pyrethroid concentrations (in the nM range) reached in environmen-
tally pyrethroid-exposed humans. By contrast, allethrin and tetramethrin cis-stimulated
OATP2B1 activity and failed to alter activities of OATP1B3, OAT1 and MATE2-K, whereas
P-glycoprotein activity was additionally moderately inhibited. Twelve other pyrethoids used at
100 μM did not block activities of the various investigated transporters, or only moderately
inhibited some of them (inhibition by less than 50%). In silico analysis of structure-activity
relationships next revealed that molecular parameters, including molecular weight and lipo-
philicity, are associated with transporter inhibition by allethrin/tetramethrin and successfully
predicted transporter inhibition by the pyrethroids imiprothrin and prallethrin. Taken together,
these data fully demonstrated that two pyrethoids, i.e., allethrin and tetramethrin, can act as
regulators of the activity of various ABC and SLC drug transporters, but only when used at
high and non-relevant concentrations, making unlikely any contribution of these transporter
activity alterations to pyrethroid toxicity in environmentally exposed humans.
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Introduction
Pyrethroid insecticides constitute presently one of the most widespread class of synthetic pesti-
cides [1]. These compounds are structurally divided into two types, i.e., type I pyrethroids con-
taining a cyclopropane carboxylic acid structure, and type II pyrethroids having an α-cyano
group attached to a benzylic carbon. They are commonly used in agriculture, in food storage
and transportation and in indoor and outdoor residential settings. Humans are thought to be
widely exposed to these pesticides [2, 3], especially through the diet [4], because pyrethroids
are frequently detected in some fruits and vegetables [5]. Additionally, dusts and surfaces can
contribute to pyrethroid exposure at residences [6], whereas occupational exposure to pyre-
throids has also to be taken into account, notably in agricultural workers [7].
The insecticidal actions of pyrethroids depend on their ability to bind to voltage-gated
sodium channels of insect nerves and to prevent their closure, leading by this way to perma-
nent depolarization of axonal membranes and paralysis [8]. Pyrethroids can also impair mam-
mal ionic channels, including voltage-gated sodium or calcium channels and voltage- and
ligand-gated chloride channels [9]. Mammals, including humans, are however considered as
rather poorly sensitive to toxic effects of pyrethroids, even if human poisoning can lead to
severe neurotoxicity, resulting in tremor syndrome for type I pyrethroids and choreoathetosis
with salivation syndrome for type II pyrethroids [10]. Chronic exposure to some pyrethroids
may moreover result in developmental neurotoxicity and nigrostriatal dopaminergic neurode-
generation, thus favoring Parkinson’s disease and other neurodegenerative diseases [11], that
are also thought to be promoted by other chemical classes of pesticides [12]. Pyrethroids may
additionally contribute in a notable way to deleterious effects of pesticide mixtures [13].
Besides ion channels, other molecular targets of pyrethroids have been described in mam-
mals. It is notably the case for γ-aminobutyric acid receptors [14] and for several hormone
receptors [15], which may contribute to endocrine disruption properties of pyrethroids [16].
Pyrethroids can also activate drug sensing receptors such as pregnane X receptor (PXR) [17]
and constitutive androstane receptor (CAR) [18]; by this way, they have been shown to up-
regulate expression and activity of some major drug metabolizing enzymes like cytochrome
P-450 (CYP) 3A4 and CYP2B6 in human hepatic cells [19, 20], and thus to modulate drug
metabolizing pathways [21]. In addition to CYPs, pyrethroids may impact mammalian drug
transporters, which contribute in a major way to xenobiotic detoxification [22] and are often
coordinately regulated with drug metabolizing enzymes [23]. Indeed, activity of P-glycopro-
tein (P-gp), an ATP-binding cassette (ABC) efflux pump encoded by the multidrug resistance
(MDR) 1 gene/ABCB1 and handling a broad range of amphiphilic cationic drugs as well as
various endogenous lipids [24, 25], has been shown to be inhibited by some pyrethroids [26,
27]. The ABC efflux pump breast cancer resistance protein (BCRP/ABCG2) may also interfere
with pyrethroids because its ATPase activity is blocked by the pyrethroids permethrin and
cypermethrin [28]. Moreover, indirect evidence for the handling of the pyrethroids deltame-
thrin, cis-permethin and trans-permethrin by an uncharacterized influx transporter in intesti-
nal Caco-2 cells has been recently reported [29]. Data about interactions of pyrethroids with
human drug transporters remain however yet rather scarce and limited. The present study was
therefore designed to more extensively analyze the potential inhibitory effects of fourteen pyre-
throids towards activity of main ABC and solute carrier (SLC) drug transporters. These insec-
ticides correspond to type I pyrethroids (seven compounds: allethrin (also known as allethrin
1), bifenthrin, cis-permethrin, trans-permethrin, resmethrin, tefluthrin and tetramethrin) or
type II pyrethroids (seven compounds: β-cyfluthrin, λ-cyhalothrin, β-cypermethrin, deltame-
thrin, esfenvalerate, fenpropathrin and τ-fluvalinate) and can be considered as adequately
reflecting the structural and historical diversity of these pesticides. Moreover, at least some of
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them are insecticides used in large-scale commercial agricultural and domestic applications
and have already been tested in in vitro toxicity assays [30–33]. Our data demonstrate that the
pyrethroids allethrin and tetramethrin are inhibitors of various drug transporters, but only
when used at relative high concentrations likely not reached in humans environmentally
exposed to these insecticides.
Materials and Methods
Chemicals
Pyrethroids were provided by Sigma-Aldrich (Saint-Quentin Fallavier, France) and Cluzeau
Info Labo (Sainte-Foy-La-Grande, France). The chemical structures of the fourteen pyrethroids
whose the potential inhibitory effects towards activity of drug transporters were extensively tested
are shown in S1 Fig. It is noteworthy that pyrethroid insecticides generally have complex configu-
rations and contain one to three chiral centers, thus resulting in two to eight stereoisomers, with
only some of them displaying insecticide properties [9, 34, 35]. Most, if not all, of these insecti-
cides can therefore be theoretically considered as mixtures of geometric and optical isomers,
knowing however that some commercial preparations of pyrethroids available on the market
may contain only one or some of possible stereoisomers [34]. Unfortunately, the exact composi-
tion and stereoisomer proportion of the pyrethroids used in the present study were not provided
by the suppliers. The total number of possible stereoisomers for each of the fourteen pyrethroids
extensively analyzed in the study is given in S1 Table. Pyrethroids were initially prepared as stock
solutions (50 mM) in dimethyl sulfoxide. Such stock solutions were next dissolved in the trans-
port assay medium described below, for getting working pyrethroid concentrations tested on
transporter activities. Rhodamine 123, verapamil, probenecid, amitriptyline, fumitremorgin C,
fluorescein, 4’,6’-diamidino-2-phenylindole (DAPI), and tetra-ethylammonium bromide (TEA)
were purchased by Sigma-Aldrich, whereas carboxy-2,7-dichlorofluorescein (CF) diacetate and
Hoechst 33342 were from Life Technologies (Saint Aubin, France). [1-14C]-TEA (sp. act. 3.5
mCi/mmol), [6,7-3H(N)]-estrone-3-sulfate (E3S) (sp. act. 54 Ci/mmol) and 3,4-[Ring-2,5,6-3H]-
dihydroxyphenylethylamine (dopamine) (sp. act. 46 Ci/mmol) were from Perkin-Elmer (Boston,
MA, USA). All other chemicals were commercial products of the highest purity available.
Cell culture
P-gp-overexpressing mammary MCF7R cells, parental MCF7 cells [36] and multidrug resis-
tance-associated protein (MRP) 2/ABCC2-expressing human hepatoma HuH-7 cells [37] were
cultured in Dulbecco’s modified Eagle medium (DMEM) (Life Technologies), supplemented
with 10% (vol/vol) fetal calf serum, 20 IU/mL penicillin and 20 μg/mL streptomycin. BCRP-
transfected HEK293 cells (HEK-BCRP cells) [38], kindly donated by Pr X. Decleves (Faculty of
Pharmacy, University Paris-Descartes, Paris, France), were cultured in DMEM supplemented
with 10% (vol/vol) fetal calf serum, 100 IU/mL amoxicillin, 100 μg/mL erythromycin and 2000
μg/mL G418. Organic anion transporter polypeptide (OATP) 1B1/SLCO1B1- and OATP1B3/
SLCO1B3- transfected CHO cells (CHO-OATP1B1 and CHO-OATP1B3 cells) were cultured
in DMEM-low glucose (1 g/L) containing 20 IU/mL penicillin, 20 μg/mL streptomycin, 10%
(vol/vol) fetal calf serum, 50 μg/mL proline and 500 μg/mL G418, as previously reported [39];
CHO wild type cells were maintained in the cell medium, without however G418. HEK293
cells overexpressing organic cation transporter (OCT) 1/SLC22A1 (HEK-OCT1 cells), OCT2/
SLC22A2 (HEK-OCT2 cells), multidrug and toxin extrusion transporter (MATE)1/SLC47A1
(HEK-MATE1 cells), organic anion transporter (OAT) 1/SLC22A6 (HEK-OAT1 cells), OAT3/
SLC22A8 (HEK-OAT3 cells) and OATP2B1/SLCO2B1 (HEK-OATP2B1 cells) were prepared
by transduction of HEK293 cells by lentiviral pLV-EF1-hOCT1-hPGK-GFP, pLV-EF1-hOCT2-
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hPGK-GFP, pLV-EF1-hMATE1-hPGK-GFP, pLV-EF1-hOAT1-hPGK-GFP, pLV-EF1-hOAT3-
hPGK-GFP, pLV-EF1-hOATP2B1-hPGK-GFP or pLV-EF1-hNTCP-hPGK-GFP vector, as
previously described [40]. Control HEK293 cells (HEK-MOCK cells) were obtained in parallel
by transduction of an empty lentiviral PLV-EF1-hPGK-GFP vector. Construction of the lenti-
viral vectors, production of lentivirus supernatants, transduction of HEK293 cells, cloning and
initial characterization of HEK-OCT1, HEK-OCT2, HEK-MATE1, HEK-OAT1, HEK-OAT3
and HEK-OATP2B1 cells were performed by Vectalys (Labège, France). Transduced HEK293
cells were next routinely cultured in DMEM medium supplemented with 10% (vol/vol) fetal calf
serum, 20 IU/mL penicillin, 20 μg/mL streptomycin, 1% (vol/vol) MEM non-essential amino
acids solution (Life Technologies) and 1 μg/mL insulin.
For transport assays, cells were usually seeded in 48-multiwell FalconTM tissue culture-
treated polystyrene or CorningTM BioCoatTM poly-D-lysine plates (Corning Incorporated,
NY, USA). The type of multiwell plates, the initial cell seeding and the number of culture days
before performing transport assays are indicated for each cell line/clone in S2 Table.
ABC and SLC transporter activity
The effects of pyrethroids on activity of ABC and SLC transporters were determined through
measuring cellular accumulation or retention of fluorescent or radiolabeled reference sub-
strates for transporters, in the presence or absence of reference inhibitors, as previously
described [41]. The nature of cells and reference substrates and inhibitors used for transport
assays are summarized in S3 Table.
For accumulation assays (performed for all transporters, excepted BCRP), transporter-
expressing cells usually cultured in 48-well plates were first incubated at 37˚C with reference
substrates in the absence (control) or presence of pyrethroids or reference inhibitors, in a
well-defined transport assay medium [42], consisting of 136 mM NaCl, 5.3 mM KCl, 1.1mM
KH2PO4, 0.8 mM MgSO4, 1.8 mM CaCl2, 10 mM HEPES, 11 mM D-glucose and adjusted to
pH = 7.4 (excepted for MATE transporter assays, for which pH was set to 8.4). The nature of
substrates and reference inhibitors and the incubation times with substrates, that varied
according to the transporter, were selected in agreement with previous studies [41, 43] and are
indicated in S3 Table. The total incubation volume with substrates was 200 μL/well. After
washing twice in phosphate-buffered saline (PBS) (200 μL/well/washing), cells were lysed in
distilled water (155 μL/well). An aliquot of cell lysate (5 μL) was then taken for determining
cellular protein content by the Bradford method [44]. The rest of lysate (150 μL/well) was used
for measuring intracellular accumulation of reference substrates by scintillation counting or
spectrofluorimetry using a SpectraMax Gemini SX spectrofluorometer (Molecular Devices,
Sunnyvale, CA, USA) (excitation and emission wavelengths were 485 and 535 nm, respec-
tively, for rhodamine 123 and fluorescein, and 355 and 460 nm, respectively, for DAPI).
For retention assay (used for BCRP activity), HEK-BCRP cells cultured in 48-well plates
were first loaded at 37˚C with transport assay (200 μL/well) containing 16.2 μM Hoechst
33342 for 30 min. After washing twice in PBS (200 μL/well/washing), cells were reincubated in
Hoechst 33342-free transport assay medium (200 μL/well) at 37˚C for 90 min in the absence
or presence of pyrethroids or of the BCRP reference inhibitor fumitremorgin C used at 10 μM.
Cells were next lysed in distilled water (155 μL/well) after washing twice in PBS (200 μL/well/
washing). The cell lysate was finally used for determining cellular protein content and intracel-
lular retention of Hoechst 33342 (by spectrofluorimetry: excitation and emission wavelengths
were 355 and 460 nm, respectively), as described above.
Intracellular concentrations of reference substrates were initially expressed as fluorescence arbi-
trary units (for fluorescent dye substrates) or as moles (for radiolabeled substrates) and normalized
Inhibition of Drug Transporter Activities by Pyrethroids
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to cellular protein content, determined by the Bradford method [44]. They were finally used for
calculating percentage of transporter activity, according to the following equations [41, 45]:
% ABC transporter activity ¼
ð½Substrateref inh  ½SubstratepyrethroidÞ  100
ð½Substrateref inh  ½SubstratecontrolÞ
ð1Þ
% SLC transporter activity ¼
ð½Substratepyrethroid  ½Substratref inhÞ  100
ð½Substratecontrol  ½Substrateref inhÞ
ð2Þ
with [Substratepyrethroid] = cellular concentration of reference substrate in the presence of pyre-
throid, [Substrateref inh] = cellular concentration of reference substrate in the presence of reference
inhibitor and [Substratecontrol] = cellular concentration of reference substrate in control cells not
exposed to pyrethroid or reference inhibitor.
For OCT1-mediated transport inhibition by pyrethroids, data were also expressed as per-
centages of inhibition of OCT1 activity using the following equation:
% OCT1 activity inhibition ¼ 100%   % OCT1 activity ðin the presence of pyrethroidÞ ð3Þ
The initial tested concentration of pyrethroids was 100 μM. When a pyrethroid used a this
concentration modulated transporter activity by more than 50%, the effects of various addi-
tional concentrations of the pyrethroid (from 0.1 to 300 μM) on transporter activity were ana-
lyzed, in order to determine half maximal inhibitory concentration (IC50) (for inhibitory
effects of pyrethroids) or half maximal effective concentration (EC50) (for stimulatory effects
of pyrethroids). Such concentrations were calculated using GraphPad Prism software (Graph-
Pad Software, La Jolla, CA), through nonlinear regression based on the four parameter logistic
function using the following equations:
For IC50:
A ¼
100
1þ 10ðð½I   LogIC50Þx Hill slopeÞ
ð4Þ
For EC50:
A ¼
100
1þ 10ðð½I   LogEC50Þx Hill slopeÞ
ð5Þ
where A is the percentage of transporter activity for a given concentration of pyrethroid deter-
mined as described in Eq (1) for ABC transporters and in Eq (2) for SLC transporters, [I] is the
pyrethroid concentration in the medium, and Hill slope is a coefficient describing the steep-
ness of the curve.
Dopamine accumulation in OCT1-transfected HEK293 cells
HEK-MOCK and HEK-OCT1 cells were incubated with transport assay medium containing
11 nM 3,4-[Ring-2,5,6-3H]-dopamine, in the absence or presence of the reference OCT1
inhibitor verapamil or of pyrethroids for 5 min at 37˚C in the transport assay medium
described above. After washing twice with PBS, cells were lysed in distilled water and intracel-
lular accumulation of dopamine was finally measured by scintillation counting.
Trans-stimulation assays in OCT1-transfected HEK293 cells
Trans-stimulation assays were performed as previously described [46]. Briefly, OCT1-trans-
fected HEK293 cells were first preloaded with 2 mM unlabeled TEA or 100 μM pyrethroid for
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60 min at 37˚c in the transport assay medium described above. After washing twice with PBS,
cells were next re-incubated in transport assay medium containing 29 μM [1-14C]-TEA for 5
min at 37˚C. After washing twice with PBS, cells were lysed in distilled water and intracellular
accumulation of [1-14C]-TEA was then determined by scintillation counting.
Molecular descriptor generation
Molecular descriptors were evaluated using the Dragon 6 software (Talete, Milano, Italy), that
provides 4885 molecular descriptors divided into 29 blocks (See http://www.talete.mi.it/
products/dragon_molecular_descriptor_list.pdf for a complete list of these descriptors). Pyre-
throids, initially expressed in SMILES format, were converted to 3D format using the Marvin-
View software (ChemAxon, Budapest, Hungary) before processing by Dragon 6 to obtain
molecular descriptors.
Statistical analysis
Experimental data were expressed as means ± SEM of at least three independent experiments,
each being usually performed in triplicate (for transport assays, one typical independent exper-
iment therefore corresponded to 3 independent wells on the same multiwell plate). They were
statistically analysis through the Student’s t-test or analysis of variance (ANOVA) followed by
a Dunnett’s or a Newman-Keuls post-hoc test; the criterion of significance was p< 0.05. Cor-
relation between molecular descriptor indexes and percentages of OCT1 activity inhibition by
pyrethroids was initially done with Dragon 6 software through Pearson correlation, using a
cut-off for Pearson’s correlation coefficient of r> 0.8 (positive correlation) or r < -0.8 (nega-
tive correlation), as recommended by the software user’s manual and as previously described
[47]. P-values for Pearson correlations, as well as linear regressions for molecular descriptors
exhibiting a high level of correlation with OCT1 activity inhibition (|r| > 0.92), were next
determined using GraphPad Prism software after confirmation of normality of data distribu-
tion by D’Agostino and Pearson omnibus normality test. The statistical analysis of molecular
descriptors belonging to the block of constitutional indices or to that of molecular properties
and allowing to discriminate allethrin/tetramethrin from the other pyrethroids was performed
using the unpaired Student’s t-test, which is applicable to very small sample sizes [48, 49].
Results
Effects of pyrethroids on ABC transporter activity
For investigating the effects of pyrethroids on ABC transporter activity, we used MCF7R,
HuH-7 and HEK-BCRP cells. Such cells exhibited increased accumulation (MCF7R and HuH-
7 cells) or retention (HEK-BCRP cells) of dyes substrates for P-gp (rhodamine 123), MRP2
and MRP2-like transporters (CF) or BCRP (Hoechst 33342) in response to reference inhibitors
of the pumps (verapamil for P-gp, probenecid for MRP2 and fumitremorgin C for BCRP) (S2
Fig), thus demonstrating that P-gp, MRP2 and BCRP are fully functional in these cells, as pre-
viously described [45]. By contrast, verapamil failed to enhance rhodamine 123 accumulation
in parental MCF7 cells (S2 Fig), which is fully consistent with the absence of detectable P-gp
activity in these cells; in the same way, fumitremorgin C did not augment Hoechst 33342
retention in HEK-MOCK cells (data not shown).
Pyrethroids were routinely used at 100 μM for screening their potential effects towards
drug transporter activity. This 100 μM concentration was retained because it was in the range
of those previously used to interact with the pharmacological targets of pyrethroids, i.e., volt-
age-gated sodium channels, in cultured cells [50, 51], thus underlining its potential relevance
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for in vitro studying interactions of pyrethroids with membrane proteins. P-gp activity was
found to be moderately, but significantly, inhibited (32.7% inhibition) by 100 μM allethrin
(Fig 1), whereas MRP2 and BCRP activity were more potently inhibited (83.8% and 83.9%
inhibition for MRP2 and BCRP, respectively) by the pyrethroid (Fig 1). For MRP2 inhibition,
allethrin IC50 value was 48.2 μM (S3A Fig) whereas it was 42.5 μM for BCRP inhibition (S3B
Fig). The pyrethroid tetramethrin used at 100 μM also notably decreased MRP2 activity
Fig 1. Effects of pyrethroids on ABC drug transporter activities. Activities of P-gp, MRP2 and BCRP were determined in ABC
transporter-expressing cells (MCF7R cells for P-gp, HuH-7 cells for MRP2 and HEK-BCRP cells), in the absence or presence of reference
inhibitors or various pyrethroids (each used at 100 μM), as described in Materials and Methods. Data are expressed as percentages of
activities found in untreated control cells, arbitrarily set at 100% and indicated by dotted lines on graphs; they are the means ± SEM of three
independent assays, each being performed in triplicate. *, p<0.05 when compared to untreated control cells.
doi:10.1371/journal.pone.0169480.g001
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(58.3% inhibition) and BCRP activity (67.1% inhibition), whereas P-gp activity was more
weakly impaired (24.5% inhibition) (Fig 1); tetramethrin IC50 values were 65.5 μM (for MRP2
inhibition) (S3A Fig) and 72.5 μM (for BCRP inhibition) (S3B Fig). For P-gp, because 100 μM
allethrin and 100 μM tetramethrin inhibited activity by less than 50%, IC50 values may be pre-
dicted to be higher than 100 μM. Other pyrethroids used at 100 μM did not significantly
inhibit P-gp, MRP2 or BCRP activity (Fig 1).
Effects of pyrethroids on organic anion SLC transporter activity
For investigating effects of pyrethroids on activity of organic anion SLC transporters, i.e.,
OATPs and OATs, we used OATP1B1-, OATP1B3-, OATP2B1-, OAT1- and OAT3-trans-
fected cells. As shown in S4 Fig, these cells exhibited increased accumulation of reference
substrates, i.e., E3S for OATP1B1 and OATP2B1 and fluorescein for OATP1B3, OAT1 and
OAT3, when compared to OATP- or OAT-untransfected counterparts; moreover, the OATP
inhibitor probenecid was able to reduce accumulation of reference substrates only in OATP-
and OAT-transfected cells (S4 Fig). Taken together, these data indicated that OATPs and
OATs were fully functional in OATP- and OAT-transfected cells.
As shown in Fig 2, allethrin and tetramethrin used at 100 μM, were found to markedly
inhibit OATP1B1 activity, by more than 85%; corresponding IC50 values were 16.5 μM and
5.7 μM for allethrin and tetramethrin, respectively (S5A Fig). Other pyrethroids did not inhibit
OATP1B1 activity or only moderately inhibited it (by less than 50%), without reaching statisti-
cal significance, except for esfenvalerate (Fig 2). None of pyrethroids was found to impair
OATP1B3 activity (Fig 2). With respect to OATP2B1 activity, it was unexpectedly stimulated
by allethrin (EC50 = 37.8 μM) and tetramethrin (EC50 = 10.1 μM) (Fig 2 and S5B Fig), whereas
other pyrethroids had no significant effect (Fig 2).
τ-fluvalinate, used at 100 μM, was the only pyrethroid that decreased OAT1 activity (Fig 3);
the percentage of inhibition (42.8%) was however less than 50%, which precluded determina-
tion of IC50 value. τ-fluvalinate also inhibited OAT3 activity, but only in a marginal and non-
significant manner (15.6% inhibition) (Fig 3). By contrast, OAT3 activity was more strongly
and significantly inhibited by 100 μM allethrin (74.8% inhibition) and 100 μM tetramethrin
(69.3% inhibition), whereas other pyrethroids failed to impair it (Fig 3); IC50 values for OAT3
inhibition were 69.4 μM (allethrin) and 77.6 μM (tetramethrin) (S5C Fig).
Effects of pyrethroids on organic cation SLC transporter activity
For analyzing effects of pyrethroids on activity of organic cation SLC transporters, i.e., MATEs
and OCTs, we used MATE1-, MATE2-K-, OCT1- and OCT2-transfected HEK293 cells. As
shown in S6 Fig, these cells exhibited increased accumulation of reference substrates, i.e., TEA
for MATE1 and MATE2-K, DAPI for OCT1 and rhodamine 123 for OCT2 when compared to
HEK-MOCK cells; moreover, reference inhibitors (verapamil for MATEs and OCT1 and ami-
triptyline for OCT2) reduced accumulation of reference substrates in MATE- and OCT-trans-
fected cells, but not in HEK-MOCK cells (S6 Fig). Taken together, these data indicated that
MATEs and OCTs were fully functional in MATE- and OCT-transfected cells.
As shown in Fig 4, allethrin and tetramethrin, used at 100 μM, markedly inhibited MATE1
activity, by more than 79%; corresponding IC50 values were 50.2 μM and 47.5 μM for allethrin
and tetramethrin, respectively (S7A Fig). Other pyrethroids did not significantly inhibit
MATE1 activity (Fig 4). None of pyrethroids was found to impair MATE2-K activity (Fig 4).
With respect to OCT1 activity, it was markedly inhibited by 100 μM allethrin (87.9% inhibi-
tion) and 100 μM tetramethrin (73.8% inhibition); corresponding IC50 values, i.e., 2.6 μM (alle-
thrin) and 4.9 μM (tetramethrin), were rather low (S7B Fig). Pyrethroids such as β-cyfluthrin,
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λ-cyhalothrin, β-cypermethrin, deltamethrin, fenpropathrin, trans-permethrin, resmethrin and
tefluthrin also significantly inhibited OCT1 activity, but in a weaker manner; OCT1 inhibition
thus ranged from 30.1% (β-cypermethrin) to 48.8% (resmethrin) (Fig 4). By contrast, bifenthrin,
cis-permethrin, esfenvalerate and τ-fluvalinate failed to significantly alter OCT1 activity (Fig 4).
Allethrin and tetramethrin were finally also shown to markedly inhibit OCT2 activity (Fig 4);
IC50 values were 42.6 μM (allethrin) and 11.2 μM (tetramethrin) (S7C Fig). OCT2 activity was
Fig 2. Effects of pyrethroids on OATP activities. Activities of OATP1B1, OATP1B3 and OATP2B1 were determined in OATP-transfected-
cells in the absence or presence of reference inhibitors or various pyrethroids (each used at 100 μM), as described in Materials and Methods.
Data are expressed as percentages of activities found in untreated control cells, arbitrarily set at 100% and indicated by dotted lines on graphs;
they are the means ± SEM of three independent assays, each being performed in triplicate. *, p<0.05 when compared to untreated control cells.
doi:10.1371/journal.pone.0169480.g002
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Fig 3. Effects of pyrethroids on OAT activities. Activities of OAT1 and OAT3 were determined in OAT-
transfected HEK cells in the absence or presence of reference inhibitors or various pyrethroids (each used at
100 μM), as described in Materials and Methods. Data are expressed as percentages of activities found in
untreated control cells, arbitrarily set at 100% and indicated by dotted lines on graphs; they are the means ±
SEM of three independent assays, each being performed in triplicate. *, p<0.05 when compared to untreated
control cells.
doi:10.1371/journal.pone.0169480.g003
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also counteracted by β-cypermethrin, τ-fluvalinate, trans-permethrin and tefluthrin, but in a
weaker manner with a percentage of inhibition around 25% (Fig 4). Other pyrethroids failed to
impair OCT2-mediated transport (Fig 4).
Fig 4. Effects of pyrethroids on MATE and OCT activities. Activities of MATE1, MATE2-K, OCT1 and OCT2 were determined in MATE- or
OCT-transfected HEK cells, in the absence or presence of reference inhibitors or various pyrethroids (each used at 100 μM), as described in
Materials and Methods. Data are expressed as percentages of activities found in untreated control cells, arbitrarily set at 100% and indicated by
dotted lines on graphs; they are the means ± SEM of three independent assays, each being usually performed in triplicate. *, p<0.05 when
compared to untreated control cells.
doi:10.1371/journal.pone.0169480.g004
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Characterization of pyrethroids-mediated OCT1 inhibition
We next focused on pyrethroids-mediated OCT1 inhibition. Indeed, OCT1 can be considered
as the drug transporter most impacted by pyrethroids because it was the transporter most sen-
sitive to allethrin and tetramethrin according to IC50 values (S7B Fig) and it was also the trans-
porter significantly inhibited by the largest number of pyrethroids, as 10/14 pyrethroids
significantly impaired its activity (Fig 4).
We first determined whether allethrin and tetramethrin can inhibit OCT1-mediated trans-
port of endogenous substrates such as dopamine. HEK-OCT1 cells exhibited enhanced verapa-
mil-inhibitable accumulation of dopamine comparatively to HEK-MOCK cells (Fig 5A), thus
fully confirming that OCT1 handles dopamine [52]. Allethrin used at 10, 100 or 300 μM was
found to significantly inhibit this OCT1-mediated transport of dopamine (Fig 5B); tetrame-
thrin also decreased it, but only when used at 100 or 300 μM (Fig 5B). Allethrin and tetrame-
thrin used at 100 μM were next shown to markedly cis-inhibit accumulation of the reference
OCT1 substrate TEA in HEK-OCT1 cells (Fig 6A). Finally, we investigated whether allethrin
and tetramethrin can trans-stimulate TEA uptake, which may constitute an argument in favor
of the transport of the two pyrethroids by OCT1 [46]. Pre-loading with allethrin and tetrame-
thrin however resulted in trans-inhibition, and not trans-stimulation, of radiolabeled TEA
uptake (Fig 6B). By contrast, pre-loading with unlabeled TEA led to a trans-stimulation of
radiolabeled TEA uptake (Fig 6B), as expected for an OCT1 substrate like TEA [46].
In order to identify the specific physico-chemical properties associated to OCT1 inhibition
by pyrethroids, molecular descriptors, including 0D-constitutional, 1D-structural, 2D-topo-
logical and 3D-geometrical descriptors, were determined using Dragon 6 software. Putative
correlations with OCT1 activity inhibition were next analyzed using Pearson’s correlation test.
Using a cutoff of |r|> 0.8, 602 molecular descriptors were found to be correlated with inhibi-
tion of OCT1 activity; the correlation was positive (r> 0.8) or negative (r< -0.8) for 93 and
509 descriptors, respectively (Table 1). These molecular descriptors associated with OCT1
inhibition belong to different blocks of descriptors, especially those of 2D-matrix based
descriptors (n = 350), of edge adjacency indices (n = 85), of topological indices (n = 26), of
3D-MoRSE descriptors (n = 24) and of walk and path counts (n = 20) (Table 1). A complete
list of these descriptors is given in S1 File. Notably, lipophilicity, evaluated through octanol-
water partition coefficients (LogP) calculated using Moriguchi LogP model (MLOGP), was
negatively correlated to OCT1 inhibition, whereas no correlation was found for molecular
weight (MW) or number of hydrogen bond acceptors (nHAcc) and donors (nHDon) (S1 File).
When a more stringent cut-off value of |r|> 0.92 was applied, 9 molecular descriptors were
found to be correlated with OCT1 activity inhibition (S4 Table); linear regression analysis next
confirmed a highly significant linear relation between the index values of these descriptors and
the percentages of OCT1 activity inhibition (S8 Fig). Such molecular descriptors exclusively
belong to the category of 2D topological indexes, notably to walk and path counts (S4 Table).
Determination of basic molecular descriptors discriminating multi-
transporter-interacting pyrethroids (allethrin/tetramethrin) from other
pyrethroids
Allethrin and tetramethrin exhibit a rather large, but specific, profile of transporter inhibition,
because they markedly decreased activity of various transporters, including MRP2, BCRP,
OATP1B1, OAT3, MATE1, OCT1 and OCT2, whereas other pyrethroids concomitantly
exerted no, or only moderate or marginal, inhibitory effects. In addition, allethrin and tetra-
methrin, unlike other pyrethroids, stimulated OATP2B1 activity (Fig 2). Molecular features
restricted to allethrin and tetramethrin may therefore be hypothesized to be involved in the
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regulations of drug transporter activities caused by the two pyrethroids. In order to identify
such physical-chemical parameters, we compared constitutional indices and molecular prop-
erties from allethrin and tetramethrin with those of other pyrethroids, because important
Fig 5. Effects of allethrin and tetramethrin on OCT1-mediated transport of dopamine. (A) HEK-OCT1
and HEK-MOCK cells were incubated with 11 nM 3,4-[Ring-2,5,6-3H]-dopamine in the absence or presence
of the reference OCT1 inhibitor verapamil (100 μM) for 5 min at 37˚C. Intracellular accumulation of 3,4-[Ring-
2,5,6-3H]-dopamine was then determined by scintillation counting. Data are expressed as pmol/μg protein
and are the means ± SEM of three independent experiments, each being performed in triplicate. *, p<0.05.
(B) HEK-OCT1 cells were incubated with 11 nM 3,4-[Ring-2,5,6-3H]-dopamine in the absence or presence of
various concentrations (10, 100 and 300 μM) of allethrin or tetramethrin. Intracellular accumulation of 3,4-
[Ring-2,5,6-3H]-dopamine was then determined by scintillation counting. Data are expressed as percentages
of OCT1-mediated transport of dopamine in control pyrethroid-unexposed cells, determined by subtracting
accumulation of dopamine in HEK-MOCK cells from that in HEK-OCT1 cells in the absence of pyrethroids,
arbitrarily set at 100% and indicated by a dotted line on the graph. They are the means ± SEM of at least three
independent assays, each being performed in triplicate. *, p<0.05 when compared to untreated control cells.
doi:10.1371/journal.pone.0169480.g005
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Fig 6. Cis- and trans-inhibitory effects of allethrin and tetramethrin towards OCT1-mediated transport
of TEA. (A) HEK-OCT1 cells were incubated with 29 μM [1-14C]-TEA for 5 min at 37˚C in the absence (control)
or presence of 100 μM verapamil, 100 μM allethrin or 100 μM tetramethrin. Intracellular accumulation of TEA
was then determined by scintillation counting. Data are expressed as percentages of TEA accumulation in
control cells and are the means ± SEM of three independent experiments, each being performed in triplicate.
*, p<0.05 when compared to control cells. (B) HEK-OCT1 cells were first incubated for 60 min at 37˚c in the
absence (control) or presence of 2 mM unlabeled TEA, 100 μM allethrin or 100 μM tetramethrin. After washing,
cells were next re-incubated with 29 μM [1-14C]-TEA for 5 min at 37˚C. Intracellular accumulation of [1-14C]-
TEA was then determined by scintillation counting. Data are expressed as percentages of TEA accumulation in
control cells and are the means ± SEM of three independent experiments, each being performed in triplicate.
*, p<0.05 when compared to control cells.
doi:10.1371/journal.pone.0169480.g006
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Table 1. Repartition of molecular descriptors correlated with OCT1 activity inhibition by pyrethroids (|r|>0.80).
Dragon ID
Block
Block
category
Block description Number of
descriptors
Number of correlated descriptors Percentage of
Correlated descriptors
in each block
Percentage of total
correlated
descriptorsPositiveCorrelation
(r > 0.8)
Negative
Correlation (r <
-0.8)
1 0D-
descriptors
Constitutional
descriptors
43 2 7 20.9 1.5
2 0D-
descriptors
Ring descriptors 32 1 4 15.6 0.8
3 2D-
descriptors
Topological indices 75 1 25 34.7 4.3
4 2D-
descriptors
Walk and path
counts
46 0 20 43.5 3.3
5 2D-
descriptors
Connectivity
indices
37 0 7 18.9 1.2
6 2D-
descriptors
Information indices 48 0 9 18.8 1.5
7 2D-
descriptors
2D matrix-based
descriptors
550 36 314 63.6 58.1
8 2D-
descriptors
2D
autocorrelations
213 4 3 3.3 1.2
9 2D-
descriptors
Burden
eigenvalues
96 0 6 6.3 1.0
10 2D-
descriptors
P_VSA-like
descriptors
45 1 1 4.4 0.3
11 2D-
descriptors
ETA indices 23 1 8 39.1 1.5
12 2D-
descriptors
Edge adjacency
indices
324 8 77 26.2 14.1
13 3D-
descriptors
Geometrical
descriptors
38 0 5 13.2 0.8
14 3D-
descriptors
3D matrix-based
descriptors
90 3 2 5.6 0.8
15 3D-
descriptors
3D
autocorrelations
80 1 0 1.3 0.2
16 3D-
descriptors
RDF descriptors 210 0 2 1.0 0.3
17 3D-
descriptors
3D-MoRSE
descriptors
224 20 4 10.7 4.0
18 3D-
descriptors
WHIM descriptors 114 0 0 0.0 0.0
19 3D-
descriptors
GETAWAY
descriptors
273 0 9 3.3 1.5
20 3D-
descriptors
Randic molecular
profiles
41 1 0 2.4 0.2
21 0D-
descriptors
Functional group
counts
154 2 2 2.6 0.7
22 1D-
descriptors
Atom-centred
fragments
115 3 0 2.6 0.5
23 1D-
descriptors
Atom-type E-state
indices
170 1 1 1.2 0.3
24 2D-
descriptors
CATS 2D 150 0 0 0.0 0.0
25 2D-
descriptors
2D Atom Pairs 1596 3 0 0.2 0.5
(Continued )
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descriptors for transporter inhibition are usually comprised among these basic descriptors
[53]. As shown in Table 2, values for 19 descriptors, i.e., 15 constitutional indices and 4 molec-
ular properties, were found to significantly differ between allethrin/tetramethrin and other
pyrethroids. These discriminating molecular descriptors notably correspond to molecular
weight (MW), van der Waals volume (Mv), polarizability (Mp), rotatable bond fraction
(RBF), percentage of C atoms (C%) and lipophilicity/LogP, calculated using either Moriguchi
(MLOGP) or Ghose-Crippen-Viswanadhan (ALOGP) LogP models. Allethrin/tetramethrin
thus exhibit reduced molecular weight, van der Waals volume, polarizability, percentage of C
atoms and lipophilicity when compared to other pyrethroids (Table 2). Interestingly, when
some of these descriptors were combined pairwise, they allowed to easily graphically discrimi-
nate allethrin/tetramethrin from other pyrethroids (Fig 7). Applying this graphically discrimi-
nation based on MW versus ALOGP or on C% versus Mv to three type I pyrethroids not
previously analyzed in the present study, i.e., imiprothrin, prallethrin and phenothrin, allowed
to predict that imiprothrin and prallethrin, unlike phenothrin, may interact with drug trans-
porter activities (Fig 8A). This prediction was next validated through demonstrating that imi-
prothrin and prallethrin, but not phenothrin, inhibited OCT1, OCT2 and OAT3 activities and
cis-stimulated that of OATP2B1 when used at 100 μM (Fig 8B); imiprothrin and prallethrin,
like allethrin and tetramethrin (Fig 3), however failed to alter OAT1 activity (Fig 8B).
Discussion
Previous studies have shown that some pesticides, including pyrethroids, may interact with
drug transporters [26, 27, 54, 55]. The data reported in the present study fully support this
hypothesis through demonstrating that the type I pyrethroids allethrin and tetramethrin inhib-
ited various ABC and SLC drug transporters (See Table 3 for a summary of drug transporter
activity regulation by these two pyrethroids). The type I pyrethroids imiprothrin and pralle-
thrin were additionally shown to interact with OCT1, OCT2, OAT3 and OATP2B1 activities.
By contrast, other type I or type II pyrethroids, did not, or only rather very moderately or mar-
ginally, impair drug transporter activities.
Allethrin and tetramethrin significantly inhibited activities of the drug efflux pumps P-gp,
MRP2 and BCRP and those of the SLC transporters OATP1B1, OAT3, MATE1, OCT1 and
OCT2. The potency of inhibition nevertheless depends on transporters (Table 3). According
to IC50 values, that constitute the main parameter to be considered for drug transporter in-
hibition, notably under a regulatory point of view [22], transporter ranking (from the most
inhibited to the less inhibited transporter) was OCT1>OATP1B1>BCRP>OCT2>MRP2>
MATE1>OAT3>P-gp for allethrin and OCT1>OATP1B1>OCT2>MATE1>MRP2>
BCRP>OAT3>P-gp for tetramethrin. The two pyrethroids also interacted with OATP2B1
Table 1. (Continued)
Dragon ID
Block
Block
category
Block description Number of
descriptors
Number of correlated descriptors Percentage of
Correlated descriptors
in each block
Percentage of total
correlated
descriptorsPositiveCorrelation
(r > 0.8)
Negative
Correlation (r <
-0.8)
26 3D-
descriptors
3D Atom Pairs 36 0 0 0.0 0.0
27 others Charge descriptors 15 0 0 0.0 0.0
28 others Molecular
properties
20 0 3 15 0.5
29 others Drug-like indices 27 5 0 18.5 0.9
doi:10.1371/journal.pone.0169480.t001
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activity, which was cis-stimulated. Only OATP1B3, OAT1 and MATE2-K activities were not
altered by the two pyrethroids. The fact that allethrin and tetramethrin failed to interact with
these drug transporters, associated to the stimulation of OATP2B1 and to the differential sensi-
tivities of inhibited transporters, discards any general and non-discriminating inhibitory effect
of allethrin and tetramethrin towards membrane transporter activities. In addition, IC50 for
transporter inhibition by allethrin and tetramethrin range from 2.6 μM to 77.6 μM, and such
values are generally much higher than pyrethroid concentrations (around 0.5–2 μM) usually
required for interacting with sodium channels in primary cultured mammalian cells [56],
making unlikely that drug transporter inhibition by pyrethroids may be due to alteration of
sodium channel activity. This conclusion is also fully supported by the fact that the majority
of pyrethroids, excepted allethrin, tetramethrin, imiprothrin and prallethrin, failed to inhibit
transporters in a major and notable way, even if they are all presumed to efficiently alter
sodium channel activity [35]. Interactions of some pyrethroids such as allethrin and tetrame-
thrin with various drug transporters can rather be considered as specific, most likely reflecting
direct and transporter-dependent interactions of these two pyrethroids with substrate and/or
regulatory binding sites on drug transporters, as classically thought for drug transporter in-
hibitors [57]. In this context, it can be speculated that binding of allethrin and tetramethrin to
targeted transporters reflects physico-chemical properties specific to these two pyrethroids.
Such properties are likely unrelated to those underlying activity of allethrin and tetramethrin
towards sodium channels. Indeed, the sodium channels-based insecticidal activity of allethrin
and tetramethrin is strictly dependent upon the entire stereospecific structure of these insecticides
[9, 34], as for other pyrethroids inactive or poorly active on transporters. It is consequently
Table 2. Molecular descriptors discriminating allethrin/tetramethrin from other pyrethroids.
Molecular descriptor Index mean p-valuea
Name Description Block Allethrin- Tetramethrin Other pyrethroids
MW molecular weight CIb 317.0 422.7 0.0198
AMW average molecular weight CI 6.5 8.7 0.0321
Mv mean atomic van der Waals volume (scaled on Carbon atom) CI 0.590 0.666 0.0021
Mp mean atomic polarizability (scaled on Carbon atom) CI 0.631 0.691 0.135
nSK number of non-H atoms CI 23.0 28.5 0.0221
nBO number of non-H bonds CI 24.5 30.5 0.0223
SCBO sum of conventional bond orders (H-depleted) CI 29.5 39.7 0.0123
RBF rotatable bond fraction CI 0.110 0.136 0.0348
nH number of Hydrogen atoms CI 25.50 20.36 0.0478
H% percentage of H atoms CI 52.60 41.51 0.008
C% percentage of C atoms CI 39.20 45.49 0.0008
O% percentage of O atoms CI 7.25 5.78 0.0488
nCsp3 number of sp3 hybridized Carbon atoms CI 11.50 6.82 0.0004
nCsp2 number of sp2 hybridized Carbon atoms CI 7.50 14.82 0.004
AMR Ghose-Crippen molar refractivity MPc 89.45 107.59 0.0447
MLOGP Moriguchi octanol-water partition coeff.(logP) MP 3.478 4.497 0.0017
ALOGP Ghose-Crippen octanol-water partition coeff.(logP) MP 3.676 5.814 0.0034
ALOGP2 squared Ghose-Crippen octanol-water partition coeff. (logP^2) MP 13.567 34.581 0.0131
PDI packing density index MP 0.900 0.928 0.0196
a given by Student’s t test.
b constitutional indice.
c molecular property.
doi:10.1371/journal.pone.0169480.t002
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restricted to some stereoisomers and did not rely on a specific substructure reactive entity or
molecular moiety that could be identified as the toxophore conferring pyrethroid-like insec-
ticidal activity [35]. The inhibitory effects against transporter activities of allethrin and tetra-
methrin can therefore not been specifically ascribed to the pyrethroid isomers within these
mixtures that are insecticides and mammalian neurotoxicants. Further studies are therefore
likely required to investigate the exact contribution of the various tetramethrin and allethrin ste-
reoisomers not implicated in primary insecticidal and neurotoxic effects to drug transporter
Fig 7. Graphical pairwise representation of some molecular descriptors allowing to discriminate
allethrin/tetramethrin from other pyrethoids. Allethrin/tetramethrin are graphically included in a red circle,
whereas other pyrethoids are included in a green circle. MW, molecular weight; ALOGP, Ghose-Crippen-
Viswanadhan octanol-water partition coefficient; Mv, mean atomic van der Waals volume (scaled on Carbon
atom); C%, percentage of C atoms.
doi:10.1371/journal.pone.0169480.g007
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Fig 8. Effects of imiprothrin, phenothrin and prallethrin on OCT1, OCT2, OATP2B1, OAT1 and OAT3 activities. (A) Imiprothrin,
phenothrin and prallethrin were projected on graphs MW (molecular weight) versus ALOGP (Ghose-Crippen-Viswanadhan octanol-water
partition coefficient) (Right panel) and C % (percentage of C atoms) versus Mv (mean atomic van der Waals volume, scaled on Carbon atom)
(Left panel). Red and green circles were placed exactly as defined in Fig 7 and putatively discriminated pyrethroids interacting with drug
transporters (red circle) from those that do not it (green circle). (B) Activities of OCT1, OCT2, OATP2B1, OAT1 and OAT3 were determined in
transporter-transfected HEK cells in the absence or presence of reference inhibitors or of imiprothrin, phenothrin or prallethrin (each used at
100 μM), as described in Materials and Methods. Data are expressed as percentages of activities found in untreated control cells, arbitrarily set
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inhibition, knowing that the effects of drug transporter inhibitors may exhibit stereoselectivity
[58].
Physicochemical parameters involved in drug transporter inhibitory effects exerted by alle-
thrin and tetramethrin likely include constitutional indices, such as molecular weight and
polarizability, and molecular properties, such as hydrophobicity (LogP), which were found to
significantly discriminate allethrin/tetramethrin from other pyrethroids. Importantly, these
basic descriptors have already been shown to be crucial for inhibition of the transporters
targeted by the two pyrethroids. Lipophilicity/LogP, molecular weight and/or molecular
polarizability thus constitute important parameters to consider for inhibiting MRP2, BCRP,
OATP1B1, OAT3, MATE1, OCT1 or OCT2 [59–65]. Interestingly, pairwise association of
some of these basic descriptors allow to easily and graphically differentiate allethrin/tetrame-
thrin from other pyrethroids not, or only poorly interacting with drug transporters. Such a
graphical discrimination was moreover used to successfully predict whether pyrethroids such
as imiprothrin, phenothrin and prallethrin may interact with activity of transporters like
OCT1, OCT2, OATP2B1, OAT1 and OAT3. This suggests that taking into consideration vari-
ous descriptors together, including not only basic descriptors but also 2D- and 3D-molecular
descriptors, would help to precisely and more extensively characterize the molecular basis of
the specific interactions of some pyrethroids with drug transporters. In particular, this may
lead to a better knowledge of the molecular features involved in cis-stimulation of OATP2B1
by pyrethroids like allethrin and tetramethrin. Cis-stimulation of OATP transporters has al-
ready been reported for other chemicals [60]. Similarly, other transporters like MRP2, OAT1,
OAT3 and MATE1 are also subjected to cis-stimulation by some chemicals [61, 62, 66]. The
molecular mechanisms that underlie such cis-stimulatory effects remain however yet poorly
characterized.
Among transporters targeted by allethrin and tetramethrin, OCT1 is likely a major one.
Indeed, allethrin and tetramethrin inhibited OCT1-mediated transport of DAPI with IC50 in
the 2–5 μM range. Moreover, OCT1-mediated transport of the dye was similarly markedly
inhibited by 100 μM imiprothrin and prallethrin, whereas other pyrethoids also impacted
OCT1 activity, although in a weaker manner. Allethrin and tetramethrin also blocked
at 100% and indicated by dotted lines on graphs; they are the means ± SEM of at least three independent assays, each being usually
performed in triplicate. *, p<0.05 when compared to untreated control cells.
doi:10.1371/journal.pone.0169480.g008
Table 3. Summary of allethrin and tetramethrin effects towards drug transporters.
Drug transporter Allethrin Tetramethrin
ABC transporter P-gp Inhibition (IC50>100 μM) Inhibition (IC50>100 μM)
MRP2 Inhibition (IC50 = 48.2 μM) Inhibition (IC50 = 65.5 μM)
BCRP Inhibition (IC50 = 42.5 μM) Inhibition (IC50 = 72.5 μM)
SLC transporter OATP1B1 Inhibition (IC50 = 16.5 μM) Inhibition (IC50 = 5.7 μM)
OATP1B3 No effect (up to 100 μM) No effect (up to 100 μM)
OATP2B1 Stimulation (EC50 = 37.8 μM) Stimulation (EC50 = 10.1 μM)
OAT1 No effect (up to 100 μM) No effect (up to 100 μM)
OAT3 Inhibition (IC50 = 69.4 μM) Inhibition (IC50 = 77.6 μM)
MATE1 Inhibition (IC50 = 50.2 μM) Inhibition (IC50 = 47.5 μM)
MATE2-K No effect (up to 100 μM) No effect (up to 100 μM)
OCT1 Inhibition (IC50 = 2.6 μM) Inhibition (IC50 = 4.9 μM)
OCT2 Inhibition (IC50 = 42.6 μM) Inhibition (IC50 = 11.2 μM)
doi:10.1371/journal.pone.0169480.t003
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OCT1-mediated transport of the reference OCT1 substrate TEA, as well as that of the endoge-
nous substrate dopamine. Inhibition of OCT1-related transport of dopamine by the two pyre-
throids was however rather less marked than that of DAPI; indeed, allethrin used at 10 μM
reduced OCT1-mediated DAPI and dopamine accumulation by 73.7% and 51.6%, respec-
tively, whereas 10 μM tetramethrin decreased DAPI uptake by 66.4%, but failed to significantly
alter that of dopamine (S7B Fig and Fig 5). This likely illustrates the fact that inhibitory profiles
for a transporter can vary according to the nature of the substrate and of drug binding sites, as
already established for various transporters, including organic cation transporters [67–69].
The mechanism by which pyrethroids like allethrin and tetramethrin down-regulate OCT1
activity remain to be determined. Because the two pyrethroids failed to trans-stimulate OCT1
activity, but rather trans-inhibited it, they are likely not substrate for OCT1. This may suggest
that they do not act through a competitive mechanism toward the transport drug binding site
on OCT1. High lipophilicity has been previously shown to be positively correlated to OCT1
inhibition, whereas a high molecular dipole moment and many hydrogen bonds were nega-
tively correlated and molecular weight was not correlated [63]. In agreement with these data,
we have found that molecular weight was also not correlated with OCT1 inhibition by pyre-
throids. By contrast, LogP was negatively correlated for pyrethroids, whereas the number of
hydrogen bonds as well as those of hydrogen bond acceptors and donors were not correlated.
The reason for these discrepancies between our study and that of Ahlin et al. [63] is unclear,
but could be linked to the small number and the relative structural homology of pyrethroids
analyzed in the present study (n = 14) when compared to the larger number of structurally-
diverse chemicals (n = 191) previously investigated [63]. Moreover, all the analyzed pyre-
throids are rather lipophilic and non-charged compounds. Nevertheless, a great number of
molecular descriptors, notably 2D-matrix based descriptors, has been found to be correlated
to OCT1 activity inhibition by pyrethroids; some of them, notably some walk and path counts,
were moreover demonstrated to exhibit a highly significant linear relationship with the per-
centage of OCT1 activity inhibition. Beyond pyrethroids, further studies are likely required to
evaluate the relevance of these molecular descriptors for predicting OCT1 inhibition by diverse
structurally-unrelated chemicals.
The putative relevance of the transporter inhibitions described in vitro in the present study
to human exposure to environmental pyrethroids is probably a key-point that has to be consid-
ered. In this context, it is first noteworthy that only some of the pyrethroids tested, i.e., alle-
thrin, tetramethrin, imiprothrin and prallethrin, exhibit significant inhibitory effects towards
transporters; this indicates that such effects on drug transporters are likely idiosyncratic off-
target effects of a limited number of compounds rather than representative of effects relevant
to the toxicology of pyrethroids as a class. Moreover, blood concentrations of pyrethroids
are very low or not detected in human subjects environmentally exposed to these pesticides
(<5μg/L, i.e.,<12.8 nM for cyfluthrin, cypermethrin, deltamethrin or permethrin [70]). This
makes very unlikely that pyrethroid concentrations required to inhibit drug transporters,
which range from 2.6 μM to 77.6 μM for allethrin/tetramethrin according to IC50 values, and
are therefore much higher than those targeting ion channels [56], may be reached in vivo.
Moreover, following systemic absorption, pyrethroids are rapidly and extensively metabolized
through oxidation, ester hydrolysis and conjugation, which precludes their accumulation in
any specific tissues or organs [71]. Transporter inhibition in response to environmental expo-
sure to pyrethroids such as allethrin and tetramethrin is therefore unlikely to occur at first
view, which discards any drug-drug interactions due to drug transport impairment or any
alteration of endogenous substrate transport by environmental pyrethroids. Putative consider-
ation of the inhibitory effects of pyrethroids like allethrin and tetramethrin towards drug
transporters under a regulatory point of view for pyrethroid risk assessment can therefore be
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excluded. It should be however kept in mind that humans are likely exposed not only to a
single pyrethroid, but to other pesticides and xenobiotics, that may also interact with drug
transporters [55], as recently demonstrated for notably organochlorine pesticides [43], poly-
chlorinated biphenyls [72], diesel exhaust particle components [41] and perfluorinated surfac-
tants [73]. Plasma levels of pyrethroids, especially allethrin and tetramethrin, associated with
those of other pollutants, may therefore be sufficient to contribute to synergic or additive
inhibitory effects towards drug transporters, as already described for pesticide combinations
[74]. In addition, concentrations of pyrethroids may be much higher in the gastro-intestinal
tract (before first-pass metabolism) than in plasma, and activities of drug transporters notably
expressed at the intestinal level, especially P-gp, MRP2, BCRP, OATP2B1 and OCT1 [22, 75],
may therefore be hypothesized to be impacted by ingested pyrethroids. Moreover, characteriz-
ing concentration-dependence of transporter activity inhibition by allethrin and tetramethrin
in the present study was based on IC50 values; because IC50 values rely on substrate concentra-
tions [76], the relevance of potential transporter inhibition has likely to be challenged according
to the nature and in vivo concentrations of putative substrates. Finally, elevated concentrations
of pyrethroids are likely to occur during acute poisoning [77] and, in this case, inhibition of
transport of endogenous substrates like dopamine by allethrin or tetramethrin may contribute
to the toxicity of these pesticides.
Another points that should be considered are the putative handling of pyrethroids by drug
transporters, notably by intestinal transporters which in case of food and drinking water expo-
sure would first be encountered [29], and the consequences for toxicokinetics of these insecti-
cides. In this context, it is noteworthy that whether pyrethroids or their metabolites can be
substrates for drug transporters remains to be determined. As already discussed above, trans-
port of allethrin and tetramethrin by OCT1 is however unlikely to occur, as demonstrated by
the failure of these two chemicals to trans-stimulate OCT1 activity. In the same way, deltame-
thrin has been recently shown to be not effluxed by P-gp [78], which agrees with the fact that
this pyrethroid did not inhibit this ABC efflux pump in the present study and also failed to
alter P-gp ATPase activity [28]. Conflicting results have however been reported with respect
to interactions of pyrethroids with P-gp. Cypermethrin, esfenvalerate, fluvalinate and per-
methrin have thus been shown to inhibit P-gp activity or ATPase activity [26, 27], but they did
not alter P-gp activity in the present study. Similarly, permethrin and resmethrin inhibited
BCRP ATPase activity [28], without inhibiting BCRP activity in our study. The reasons of such
discrepancies are unclear, but they could be linked to the high concentrations of pyrethroids
used in some previous studies [26] or to the different methodological approaches retained for
investigating ABC efflux pump, i.e., ATPase activity versus effective transport of reference
substrates.
Finally, the hypothesis that pyrethroids may alter expression of drug transporters, notably
in the liver, has likely to be additionally considered. Indeed, pyrethroids can activate drug
sensing receptors like PXR and CAR [17, 18], which are well-known to be implicated in drug
transporter expression regulation [79, 80]. Activation of PXR or CAR by pyrethroids may
consequently result in up-regulation of transporters targeted by these receptors such as P-gp
[81], MRP2 [82] or MRP3 [83]. Whether such putative regulations may occur in response to
environmental concentrations of pyrethroids and may have functional consequences would
deserve further studies.
In summary, the pyrethroids allethrin and tetramethrin were found to inhibit activity of vari-
ous ABC and SLC drug transporters. Such inhibitions of drug transporters however occurred
for concentrations of the two pyrethroids much higher than those commonly expected in
response to environmental exposure, making unlikely any relevant contribution of transporter
inhibition to pyrethroid toxicity in environmentally exposed humans.
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Supporting Information
S1 File. List of molecular descriptors correlated with OCT1 activity inhibition by pyre-
throids ((|r|>0.80).
(XLSX)
S1 Table. Number of possible stereoisomers for pyrethroids.
(DOCX)
S2 Table. Parameters for transporter-expressing cell culture.
(DOCX)
S3 Table. Parameters of drug transport assays.
(DOCX)
S4 Table. Molecular descriptors highly correlated with OCT1 activity inhibition by pyre-
throids ((|r|>0.92).
(DOCX)
S1 Fig. Chemical structures of pyrethroids.
(TIF)
S2 Fig. ABC transporter activities in ABC transporter-expressing reference cell lines. P-gp,
MRP2 and BCRP activities were determined through measuring cellular accumulation (P-gp
and MRP2 activities) or retention (BCRP activity) of reference substrates (rhodamine 123 for
P-gp, CF for MRP2 and Hoechst 33342 for BCRP), in the absence or presence of reference
inhibitors (50 μM verapamil for P-gp, 2 mM probenecid for MRP2 and 10 μM fumitremorgin
C for BCRP), in parental MCF7 and P-gp-positive MCF7R cells, in MRP2-positive HuH-7
cells and in HEK-BCRP cells. Data shown are the means ± SEM of at least three independent
assays, each being performed in triplicate. , p<0.05. FAU, fluorescence arbitrary unit.
(TIF)
S3 Fig. Concentration-dependent effects of allethrin and tetramethrin towards MRP2 and
BCRP activities. (A) MRP2 and (B) BCRP activities were determined in the absence or pres-
ence of various concentrations of allethrin or tetramethrin, as described in Materials and
Methods. Data are expressed as percentages of transporter activity found in control untreated
cells, arbitrarily set at 100%; they are the means ± SEM of three independent assays, each being
performed in triplicate. IC50 values are indicated at the top of graphs.
(TIF)
S4 Fig. OATP/OAT activities in transporter-expressing reference cell clones. OATP1B1,
OATP1B3, OATP2B1, OAT1 and OAT3 activities were determined through measuring intra-
cellular accumulation of reference substrates (E3S for OATP1B1 and OATP2B1 and fluores-
cein for OATP1B3, OAT1 and OAT3), in the absence or presence of the reference inhibitor
probenecid, in OATP- or OAT-transfected cells and in control parental transporter-untrans-
fected cells. Data shown are the means ± SEM of at least three independent assays, each being
performed in triplicate. , p<0.05. FAU, fluorescence arbitrary unit.
(TIF)
S5 Fig. Concentration-dependent effects of allethrin and tetramethrin towards OATP1B1,
OATP2B1 and OAT3 activities. (A) OATP1B1, (B) OATP2B1 and (C) OAT3 activities were
determined in the absence or presence of various concentrations of allethrin or tetramethrin,
as described in Materials and Methods. Data are expressed as percentages of transporter activ-
ity found in control untreated cells, arbitrarily set at 100%; they are the means ± SEM of three
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independent assays, each being performed in triplicate. (A, C) IC50 and (B) EC50 values are
indicated at the top of graphs.
(TIF)
S6 Fig. MATE/OCT activities in transporter-expressing reference cell clones. MATE1,
MATE2-K, OCT1 and OCT2 activities were determined through measuring intracellular accu-
mulation of reference substrates (TEA for MATE1 and MATE2-K, DAPI for OCT1 and rho-
damine 123 for OCT2), in the absence or presence of reference inhibitors (verapamil for
MATEs and OCT1 and amitriptyline for OCT2), in MATE- or OCT-transfected HEK293 cells
and in control HEK-MOCK cells. Data shown are the means ± SEM of at least three indepen-
dent assays, each being usually performed in triplicate. , p<0.05. FAU, fluorescence arbitrary
unit.
(TIF)
S7 Fig. Concentration-dependent effects of allethrin and tetramethrin towards MATE1,
OCT1 and OCT2 activities. (A) MATE1, (B) OCT1 and (C) OCT2 activities were determined
in the absence or presence of various concentrations of allethrin or tetramethrin, as described
in Materials and Methods. Data are expressed as percentages of transporter activity found in
control untreated cells, arbitrarily set at 100%; they are the means ± SEM of three independent
assays, each being performed in triplicate. IC50 values are indicated at the top of graphs.
(TIF)
S8 Fig. Linear regression analysis of percentage of OCT1 activity inhibition by pyrethroids
versus molecular descriptor values. Linear regression analysis was performed for percentages
of OCT1 activity inhibition versus values of the molecular descriptors piPC02, piPC03, piPC04,
piPC05, piPC06, SpDiam_X, JGI3, SM02_EA(bo) and SM04_EA(bo). The r2 value, a measure
of the goodness of the fit, and the p-value are indicated at the top of graphs.
(TIF)
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